Clinical Overview
Ceftriaxone Sodium and Tazobactam Sodium combines an extended-spectrum third-generation cephalosporin with the potent beta-lactamase inhibitor tazobactam. Tazobactam prevents ceftriaxone hydrolysis by plasmid- and chromosome-mediated beta-lactamases, restoring full bactericidal activity. Indicated for severe polymicrobial infections, meningitis, sepsis, complicated skin/soft tissue infections, and hospital-acquired lower respiratory infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered by a trained nurse or physician via slow IV infusion over 30 minutes after aseptic reconstitution with Water for Injections. Incompatible with calcium-containing solutions. Administer once or twice daily based on clinical severity.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, nausea, local infusion site phlebitis, rash, elevated transaminases. Rare/Severe: Anaphylaxis, Clostridioides difficile colitis, hemolytic anemia, and gallbladder sludging.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in neonates receiving IV calcium. Contraindicated in cephalosporin allergy. Exercise caution in patients with hepatic and renal dysfunction simultaneously.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftriaxone 1g + Sulbactam 500mg Injection
Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.
Ceftriaxone 250 mg + Sulbactam 125 mg Injection
Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.
Ceftriaxone 500mg + Sulbactam 250mg Injection
Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.
Ceftriaxone Injection 1 g
Ceftriaxone Sodium is an essential third-generation parenteral cephalosporin bactericidal antibiotic on the WHO Model List of Essential Medicines. It features an exceptionally long elimination half-life (around 8 hours), permitting once-daily administration. Crosses the blood-brain barrier effectively. Indicated for bacterial meningitis, septicemia, community-acquired pneumonia, typhoid fever, complicated UTIs, gonococcal infections, pelvic inflammatory disease, and pre-operative surgical prophylaxis.